237 related articles for article (PubMed ID: 26442831)
1. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
Liu H; Han R; Li J; Liu H; Zheng L
J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
[TBL] [Abstract][Full Text] [Related]
3. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations.
Bisson WH; Abagyan R; Cavasotto CN
J Mol Graph Model; 2008 Nov; 27(4):452-8. PubMed ID: 18805032
[TBL] [Abstract][Full Text] [Related]
5. An insight about the mechanism of action (MoA) of R-bicalutamide on the androgen receptor homodimer using molecular dynamic.
Cavaliere F; Cozzini P
Toxicol Appl Pharmacol; 2022 Apr; 440():115953. PubMed ID: 35245614
[TBL] [Abstract][Full Text] [Related]
6. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
8. Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations.
Liu H; Wang L; Tian J; Li J; Liu H
J Cell Biochem; 2017 Sep; 118(9):2792-2801. PubMed ID: 28181296
[TBL] [Abstract][Full Text] [Related]
9. Conformational dynamics of androgen receptors bound to agonists and antagonists.
Gim HJ; Park J; Jung ME; Houk KN
Sci Rep; 2021 Aug; 11(1):15887. PubMed ID: 34354111
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer.
Osguthorpe DJ; Hagler AT
Biochemistry; 2011 May; 50(19):4105-13. PubMed ID: 21466228
[TBL] [Abstract][Full Text] [Related]
11. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
12. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
13. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
Bohl CE; Gao W; Miller DD; Bell CE; Dalton JT
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6201-6. PubMed ID: 15833816
[TBL] [Abstract][Full Text] [Related]
15. Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.
Azhagiya Singam ER; Tachachartvanich P; La Merrill MA; Smith MT; Durkin KA
J Phys Chem B; 2019 Sep; 123(36):7657-7666. PubMed ID: 31431014
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
19. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
[TBL] [Abstract][Full Text] [Related]
20. A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations.
Liu HL; Zhong HY; Song TQ; Li JZ
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28832499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
